AstraZeneca CEO on Cancer Treatment, Covid in China

The transcript covers AstraZeneca's business growth, highlighting a 60% growth rate despite COVID-19 challenges affecting cancer diagnosis and treatment. The discussion shifts to the oversupply of COVID vaccines and the focus on Evershed, a product for immunocompromised individuals. Future plans include developing antibodies for other infections and addressing the impact of COVID lockdowns in China on business operations. The CEO discusses China's innovation and leadership, and touches on succession planning within AstraZeneca, emphasizing the exciting opportunities in the industry.

What was the growth rate of the company in the first quarter?

• 45%

• 30%

• 75%

• 60%

Which area was particularly affected by COVID, impacting cancer diagnosis and treatment?

• Tokyo

• Kansai

• Osaka

• Hokkaido

Has the healthcare system returned to pre-pandemic levels for cancer diagnosis and treatment?

• Partially, varies by country

• Yes, completely

• No, not at all

• Only in developed countries

What is the name of the product focused on protecting immunocompromised individuals?

• Evershed

• Imfinzi

• Remdesivir

• Alexion

What is the company's plan for vaccine and immune therapies beyond COVID?

• Exploring antibodies for other infections

• Focusing solely on COVID vaccines

• Discontinuing vaccine research

• Developing new antibiotics

How are the COVID lockdowns in China affecting the company's operations?

• No impact at all

• Improving supply chains

• Boosting local sales

• Disrupting supply chains and treatment

What is the CEO's view on President Xi Jinping's leadership?

• Uninvolved and passive

• Unpredictable and erratic

• Restrictive and conservative

• Visionary and innovative